8th Oct 2014 07:48
LONDON (Alliance News) - Summit Corp PLC said Wednesday that it has reported positive data on its utrophin modulation programme for the treatment of Duchenne Muscular Dsytropy at the 2014 World Muscle Society Congress in Berlin.
Summit said that progress on its SMT C1100 compound shows it has "the potential to become the first utrophin modulator drug to treat all DMD patients, to be followed by second generation candidates with improved properties."
The company reported clinical data on the compound from a Phase Ib study in boys with Duchenne Muscular Dystrophy, and additionally positive preclinical data on its second generation utrophin modulator programme.
"SMT C1100 is paving the way in the clinic for utrophin modulation and the initial signs of activity point to this mechanism as a potential treatment for all boys with DMD," said Chief Executive Glyn Edwards in a statement. "Our second generation utrophin modulators build on this mechanism with the new data illustrating how they increase utrophin protein levels and improve muscle health, while having enhanced drug properties compared to the first generation drug SMT C1100."
Shares in Summit are trading up 1.7% at 150.00 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L